SCHEDULE: Lantheus Holdings Sells 7.7% Stake in Perspective Therapeutics

Lantheus Holdings, Inc. and its subsidiaries have significantly reduced their beneficial ownership in Perspective Therapeutics, Inc., selling over 8.7 million shares.

Summary

• Lantheus Holdings, Inc. and its subsidiaries (Lantheus Medical Imaging, Inc. and Lantheus Alpha Therapy, LLC) have filed an amendment to their Schedule 13D, reporting a reduction in their beneficial ownership of Perspective Therapeutics, Inc. common stock.
• The reporting persons collectively now beneficially own 8,739,011 shares, representing 7.7% of the outstanding common stock.
• This reduction is due to multiple sales of shares on the open market by Lantheus Alpha Therapy, LLC between September 4, 2026, and September 22, 2026.
• The total number of shares outstanding for Perspective Therapeutics, Inc. as of August 5, 2026, was 114,151,663, following a 1-for-10 reverse stock split.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant share sales by a major holder, indicating a potential lack of confidence or a strategic shift away from the company.

Negatives

• Lantheus Alpha Therapy, LLC sold a substantial number of shares: 167,149 on Sept 4, 92,442 on Sept 8, 65,500 on Sept 9, 13,450 on Sept 14, 750,000 on Sept 18, 215,974 on Sept 21, and 1,396,987 on Sept 22.
• The total reduction in beneficial ownership by Lantheus Holdings and its subsidiaries results in them holding only 7.7% of the company's common stock, down from a previous undisclosed but larger percentage.
• The sales occurred over a concentrated period, suggesting a deliberate divestment strategy.

Risks

• The significant sale of shares by a major holder like Lantheus Holdings could signal a lack of confidence in Perspective Therapeutics' future prospects, potentially impacting investor sentiment.
• A large block of shares being sold on the open market could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking statements or guidance from Perspective Therapeutics, Inc. are included in this filing. The filing primarily details past transactions by a significant shareholder.

Management Comments

• "Shares reported as beneficially owned represent shares directly held by Lantheus Alpha Therapy, LLC ('Lantheus Alpha'), a wholly owned direct subsidiary of Lantheus Medical Imaging, Inc. ('Lantheus Medical'). Lantheus Medical is the sole member of Lantheus Alpha and a wholly-owned subsidiary of Lantheus Holdings, Inc. ('Lantheus Holdings'). Lantheus Holdings, Lantheus Medical and Lantheus Alpha may each be deemed to have shared voting and dispositive power over all of the shares of Common Stock held by Lantheus Alpha."
• "To the best knowledge of each of the Reporting Persons, none of the individuals listed on Schedule A to this Statement beneficially owns any of the Issuer's Common Stock."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant share sales by major holders, especially those structured through subsidiaries as seen here, can be interpreted as a signal of strategic repositioning or a reduction in conviction regarding the target company's growth trajectory. This is particularly relevant in the biotechnology and therapeutics sector where investor confidence is heavily influenced by perceived future potential.

Comparison to Industry Standards

• The filing does not provide performance data for Perspective Therapeutics, Inc. that would allow for direct comparison to industry standards.
• The actions of Lantheus Holdings, a significant player in the medical imaging and diagnostics space, in divesting a substantial portion of its stake in a therapeutics company, could be a trend observed among diversified healthcare entities re-evaluating their investment portfolios.
• No specific comparable companies or projects are mentioned in relation to these share sales.

Stakeholder Impact

• Shareholders of Perspective Therapeutics, Inc. may experience negative sentiment and potential stock price decline due to the significant sale by a major holder.
• Potential investors may view the divestment by Lantheus Holdings as a negative signal, potentially affecting future investment in Perspective Therapeutics.
• Creditors and business partners of Perspective Therapeutics may monitor the situation for any signs of financial distress or strategic uncertainty.

Next Steps

• Lantheus Holdings and its subsidiaries will continue to hold their remaining 7.7% stake in Perspective Therapeutics, Inc.
• Perspective Therapeutics, Inc. will continue its operations, with the impact of this divestment on its stock price and investor relations yet to be fully determined.

Key Dates

Recommendation

The significant reduction in beneficial ownership by Lantheus Holdings, a major shareholder, indicates a potential lack of confidence or a strategic shift away from Perspective Therapeutics. This substantial divestment, detailed through multiple open market sales, is a strong negative signal that is likely to influence investor sentiment and potentially lead to a decrease in share price. Therefore, a sell recommendation is warranted for seasoned investors and institutions.

Keywords

Schedule 13D, Beneficial Ownership, Shareholder, Stock Sale, Divestment, Perspective Therapeutics, Lantheus Holdings